Dimension Expands Board
This article was originally published in Scrip
Executive Summary
Dimension Therapeutics, Inc., a company developing liver-directed treatments for diverse genetic disorders, has elected of Dr Georges Gemayel, former executive vice-president of Genzyme Corporation and Arlene M. Morris, former CEO of Syndax Pharmaceuticals, to its board of directors. Dimension has also announced that Donald J. Hayden, Jr. is leaving his position as a member of the board. Previously, Gemayel was executive chair of Vascular Magnetics Inc., Syndexa, and FoldRx Pharmaceuticals, Inc (acquired by Pfizer). And Morris was previously president and CEO of Affymax, Inc.
You may also be interested in...
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.
In Vivo’s 2024 Rising Leaders
The fifth annual listing of In Vivo’s Rising Leaders includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.